×
About 1,848 results
Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018.
https://doi.org/10.1542/peds.2017-2550
Pediatrics

Sep 5th, 2017 - This statement updates the recommendations for routine use of the seasonal influenza vaccine and antiviral medications for the prevention and treatment of influenza in children. The American Academy of Pediatrics recommends annual seasonal influenza immunization for everyone 6 months and older, including children and adolescents. Highlights for the upcoming 2017-2018 season include the followin...

Biggest Threats and Data 2019 AR Threats Report CDC’s Antibiotic Resistance Threats in the United States, 2019
https://www.cdc.gov/drugresistance/biggest-threats.html
CDC

Nov 14th, 2019 - CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) includes the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the U.S. According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. In addition, 223,900...

FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
http://www.news.sanofi.us/2019-11-04-FDA-approves-Fluzone-R-High-Dose-Quadrivalent-Influenza-Vaccine-for-adults-65-years-of-age-and-older

Nov 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. Fluzone High-Dose Quadri...

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
https://www.nejm.org/doi/full/10.1056/NEJMoa1909953
The New England Journal of Medicine; Tait, D. et. al.

Oct 28th, 2019 - BACKGROUND Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity. METHODS From August 201...

Risk Factors and Cancer | CDC
https://www.cdc.gov/cancer/risk_factors.htm

Oct 28th, 2019 - Selected risk factors (things that increase your chance of getting cancer), including tobacco and alcohol use and human papillomavirus (HPV).

Shingles - Genetics Home Reference - NIH
https://ghr.nlm.nih.gov/condition/shingles

Oct 28th, 2019 - Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a per...

Pan-viral serology implicates enteroviruses in acute flaccid myelitis
https://www.nature.com/articles/s41591-019-0613-1
Nature Medicine; Schubert, R. et. al.

Oct 20th, 2019 - Since 2012, the United States of America has experienced a biennial spike in pediatric acute flaccid myelitis (AFM)1,2,3,4,5,6. Epidemiologic evidence suggests non-polio enteroviruses (EVs) are a potential etiology, yet EV RNA is rarely detected in cerebrospinal fluid (CSF)2. CSF from children with AFM (n = 42) and other pediatric neurologic disease controls (n = 58) were investigated for intra...

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Influenza Vaccination: Updated Recommendations from ACIP
https://www.aafp.org/afp/2019/1015/p505.html

Oct 14th, 2019 - The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has released its recommendations for routine influenza vaccination in the 2019–2020 season. Updates this year include the antigenic composition of seasonal influenza vaccines available in the United States and changes related to recent regulatory actions, including labeling changes for previousl...

Nail Changes Following a Viral Infection: Photo Quiz
https://www.aafp.org/afp/2019/1015/p497.html
American Family Physician;

Oct 14th, 2019 - A seven-year-old boy presented with abnormal growth of his fingernails that began two weeks prior. He had no other symptoms, including pain or pruritus on his hands or around his nails. He did not have fevers, chills, nausea, vomiting, or change in activity. He had hand-foot-and-mouth disease two months earlier that was diagnosed based on vesicular lesions in his mouth and on his hands and feet...

Three Leading National Public Health Organizations Ring The Alarm About All-time Highs Of STDs
http://www.ncsddc.org/three-leading-national-public-health-organizations-ring-the-alarm-about-all-time-highs-of-stds/

Oct 7th, 2019 - Data released this week by the Centers for Disease Control and Prevention (CDC) show STDs have surged for the fifth consecutive year, reaching an all-time high in the U.S. These dangerous trends in chlamydia, gonorrhea, and syphilis show no sign of slowing and affect millions of lives each year in the United States. Particularly worrisome is the emerging trend of newborn syphilis (congenital sy...

California OKs pharmacists to dispense HIV prevention meds
https://apnews.com/a1491134e0c242bc95ef36ed0a9fa95e

Oct 6th, 2019 - Pharmacists in California will be able to dispense HIV prevention pills to patients without a doctor’s prescription after Gov. Gavin Newsom signed legislation Monday that supporters say will greatly reduce the spread of infection. Advocates of Senate Bill 159 say California is the first state to authorize pre-exposure prophylaxis, also called PrEP, and post-exposure prophylaxis, known as PEP...

National Update on Measles Cases and Outbreaks — United States, January 1–October 1, 2019
https://www.cdc.gov/mmwr/volumes/68/wr/mm6840e2.htm
Morbidity and Mortality Weekly Report; Patel, M. et. al.

Oct 3rd, 2019 - What is already known about this topic? Measles was eliminated in the United States in 2000. High national coverage with measles, mumps, and rubella vaccine and rapid implementation of measles control measures prevent widespread measles transmission. What is added by this report? During January–September 2019, 1,249 U.S. measles cases were reported, the highest annual number since 1992...

Seasonal Influenza Vaccination Resources for Health Professionals | CDC
https://www.cdc.gov/flu/professionals/vaccination/index.htm

Oct 2nd, 2019 - CDC Centers for Disease Control and Prevention Influenza Flu - vaccination resources for healh care professionals includes links to ACIP resources, flu vaccine information and patient education materials.

Hand-Foot-and-Mouth Disease: Rapid Evidence Review
https://www.aafp.org/afp/2019/1001/p408.html
American Family Physician; Saguil, A. et. al.

Sep 30th, 2019 - Hand-foot-and-mouth disease is caused by human enteroviruses and coxsackieviruses. Outbreaks can occur in the spring to fall and are common in North America, and most cases occur in patients younger than 10 years. Hand-foot-and-mouth disease is transmitted by fecal-oral, oral-oral, and respiratory droplet contact. Patients present with a low-grade fever, a maculopapular or papulovesicular rash ...

Opioid Use Disorder: Medical Treatment Options
https://www.aafp.org/afp/2019/1001/p416.html
American Family Physician; Coffa, D. et. al.

Sep 30th, 2019 - Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, pat...

Common Misperceptions About Buprenorphine Prescribing for Opioid Use Disorder
https://www.aafp.org/afp/2019/1001/p396.html
American Family Physician;

Sep 30th, 2019 - “Virtually every issue [that] relates to drug dependence is suffused with emotion that turns differences of opinion into controversy and leads to distortions, exaggerations, and misunderstandings.” This quotation comes from 1971 in the early days of methadone treatment. Policy makers and practitioners were wrestling with a strategy to safely use this effective medication. We are now faced wi...

What Is the Best Treatment for Advanced HIV Disease?
https://blogs.jwatch.org/hiv-id-observations/index.php/what-is-the-best-treatment-for-advanced-hiv-disease/2019/09/28/

Sep 27th, 2019 - An ongoing dialogue on HIV/AIDS, infectious diseases, all matters medical, and some not so medical.

FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks
https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-adults-and-children-all-genotypes-hepatitis-c-and-compensated-cirrhosis

Sep 25th, 2019 - The U.S. Food and Drug Administration today expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV (treatme...

U.S. FDA Clears Abbott's High Sensitivity Troponin-I Blood Test That Aids Doctors In Diagnosing Heart Attacks Faster And More Accurately
https://abbott.mediaroom.com/2019-09-25-U-S-FDA-Clears-Abbotts-High-Sensitivity-Troponin-I-Blood-Test-That-Aids-Doctors-in-Diagnosing-Heart-Attacks-Faster-and-More-Accurately

Sep 24th, 2019 - Abbott (NYSE: ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug Administration (FDA). As one of the most researched troponin diagnostic tests, doctors in the U.S. can now utilize this proven technology to help detect heart attacks faster and more accurately than contemporary troponin tests.